Global Central Nervous System Therapeutics Market Size By Disease (Neurovascular Diseases, Trauma, Mental Health), By Drug Class (Analgesics, Nervous System Drugs, Anesthetics), By Geographic Scope And Forecast

Central Nervous System Therapeutics Market Size And Forecast

Central Nervous System Therapeutics Market size was valued at USD 85.24 Billion in 2021 and is projected to reach USD 170.43 Billion by 2030, growing at a CAGR of 9.45% from 2023 to 2030.

The structure and function of the brain and spinal cord are being affected by an increase in CNS disorders such as neurodegenerative diseases, autoimmune and inflammatory diseases, genetic disorders, malignancies, and others. To treat these problems, CNS medications are required. The Global Central Nervous System Therapeutics Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Central Nervous System Therapeutics Market Definition

The brain and spinal cord parts of the central nervous system (CNS) are important aspects of the nervous system. It combines the data it receives before coordinating and managing the activity of all body parts. Neurovascular disorders, such as brain aneurysms, arteriovenous malformations (AVMs), carotid artery disease, and intracranial atherosclerotic disease, have significant health and economic impact on Americans and can result in a variety of neurological issues ranging from stroke to subarachnoid hemorrhage to disability and death. Cerebral aneurysms afflict an estimated 6 million Americans and cause up to half a million deaths globally each year, according to the Brain Aneurysm Foundation, with half of the victims being under the age of 50.

Any operation that necessitates the use of an operating microscope is referred to as microsurgery. Traditional open surgery with very small equipment and a microscope can be used to treat neurovascular disorders (microsurgery).To avoid difficulties, this sort of surgery entails working around very small, sensitive nerves and brain parts that must be treated gently and carefully. Aneurysm clipping, skull base surgery, and neurovascular surgery are all examples of microsurgery. To obtain the best possible results, neurosurgeons combine the latest microsurgery techniques with computer-guided localization and comprehensive intraoperative monitoring.

Endovascular surgery is a minimally invasive method for treating abnormalities with the blood vessels, such as an aneurysm, which is a blood vessel bulge or ballooning. It is performed inside the artery (endovascular) using a catheter introduced into the bloodstream at the groin and guided to the brain. Compared to traditional open surgery, endovascular surgery causes less discomfort, requires fewer hospital stays and has a lower risk of complications. Coiling, stenting, angioplasty, and embolization are all examples of endovascular surgery. Degenerative disc disease is a collection of symptoms that can occur as a result of the cumulative wear and tear of spinal discs or as a result of an abrupt spinal injury.

Global Central Nervous System Therapeutics Market Overview

Advancements in diagnostics, treatments, and drug discovery methodologies are driving the growth of the Central Nervous System Therapeutics Market. Furthermore, the rising demand for effective CNS therapeutic choices pushes big pharmaceutical companies to engage in research and development, paving the way for future growth. Furthermore, increased awareness of psychiatric diseases, an increase in the frequency of mental illness and lifestyle-related CNS disorders, and an increase in the elderly population all contribute to the global market’s growth. Since the last several years, the rate of acute psychological distress among teenagers and young adults has been on the rise, fueling demand for CNS therapies around the world.

However, strict & extended drug approval procedures and increasing prices of new treatments are likely to restrict the growth of the Central Nervous System Therapeutics Market. According to the WHO, dementia affects 50 million people worldwide, with approximately 60% of them residing in low- and middle-income countries. As per the Parkinson’s Foundation, there are 2.8 million people with multiple sclerosis and ten million people with Parkinson’s disease in the world. These disorders have a limited number of therapeutic choices. Currently, five authorized medications are commonly used to treat Alzheimer’s disease, and 146 clinical studies in Phases 1, 2, and 3 are enrolling participants.

Agents capsules for Parkinson’s disease when a patient’s meds aren’t functioning and Zeposia capsules for relapsing types of multiple sclerosis were recently approved by the FDA. According to Alzheimer’s Europe, the European Union’s dementia population is expected to be at 7.8 million people. Furthermore, the Harvard NeuroDiscovery Center predicts that almost 12 million Americans will be affected by neurodegenerative disorders in 30 years if no action is taken. As a result of the rising prevalence of these diseases, the medication development pipeline, and the potential of this segment, clinical trials, product launches, and strategic alliances are becoming more common.

According to the National Institute on Aging, almost 524 million people were over the age of 65 in 2010, accounting for around 8% of the global population. By 2050, this figure is predicted to reach 1.5 billion, accounting for over 16% of the global population. Brain disorders become more common as people get older. Various activities are being taken by governments and non-governmental organizations around the world to promote awareness of CNS illnesses. Organizations are also gathering money to support clinical research and development in the hopes of improving disease treatment. Every year, for example, April 11 is designated as World Parkinson’s Day.

Global Central Nervous System Therapeutics MarketSegmentation Analysis

The Global Central Nervous System Therapeutics Market is segmented on the basis of Disease, Drug Class, And Geography.

Central Nervous System Therapeutics Market, By Disease

• Neurovascular Diseases
• Trauma
• Mental Health
• Degenerative Diseases
• Infectious Diseases
• Cancer
• Other Infectious Diseases

Based on Disease, The market is divided into Neurovascular Diseases, Trauma, Mental Health, Degenerative Diseases, Infectious Diseases, Cancer, and Other Infectious Diseases. Any abnormality of the blood arteries within or supplying the brain and spine is referred to as neurovascular illness. This includes artery narrowing, which limits blood flow to the brain and raises the risk of stroke (particularly “ischemic” stroke), as well as artery weakness, which can lead to brain aneurysms and intracranial bleeding (or hemorrhagic stroke). People who have had a stroke frequently experience abrupt weakness or numbness on one side of their body. They might also have trouble speaking or seeing, as well as lose their balance or coordination. Occasionally, people will just experience minor or transient symptoms that will go away on their own.

Central Nervous System Therapeutics Market, By Drug Class

• Analgesics
• Nervous System Drugs
• Anesthetics
• Anti-Parkinson Drugs
• Anti-Epileptics
• Other Drug Classes

Based on Drug Class, The market is divided into Analgesics, Nervous System Drugs, Anesthetics, Anti-Parkinson Drugs, Anti-Epileptics, and Other Drug Classes. The peripheral and central nervous systems are both affected by Analgesic Medications. An Analgesic that reduces pain. This is particularly true with pain relievers like acetaminophen. Analgesics include medications classed as NSAIDs (nonsteroidal anti-inflammatory drugs), such as ibuprofen. Opioid and opiate compounds, as well as non-opioid pharmaceuticals, are Analgesics. They can be prescribed or purchased over the counter. For a desired therapeutic effect, several nonopioid and nonopioid-opioid formulations also operate as antipyretics and anti-inflammatory drugs.

Central Nervous System Therapeutics Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

On the basis of Regional Analysis, The Global Central Nervous System Therapeutics Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The Asia Pacific region is expected to witness a significant CAGR during the forecast period. This is primarily due to the structure and function of the brain and spinal cord are being affected by an increase in CNS disorders such as neurodegenerative diseases, autoimmune and inflammatory diseases, genetic disorders, malignancies, and others. To treat these problems, CNS medications are required.

Key Players

The “Global Central Nervous System Therapeutics Market” study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Biogen Inc, Otsuka Pharmaceutical Co. Ltd, Eli Lilly and Company, Merck KGaA, AstraZeneca, Takeda Pharmaceutical Company Limited, Novartis AG, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Private Limited, GlaxoSmithKline PLC.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• April 2021, The National Medical Products Administration (NMPA) has approved Biogen’s TECFIDERA (dimethyl fumarate) to treat relapsed multiple sclerosis, allowing the company to extend its presence in China.
• April 2021, Patients are still being recruited for phase III clinical studies of aripiprazole to treat Alzheimer’s dementia, according to Otsuka and Lundbeck.
• June 2021, GSK and iTeos Therapeutics have announced an agreement to develop and commercialize EOS-448, an anti-TIGIT monoclonal antibody that will enable novel next-generation immuno-oncology combinations.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.